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ABSTRACT Recent work suggested that the activity of extracellular signal-regulated
kinase 1/2 (ERK1/2) is increased in the retinal pigment epithelium (RPE) of age-
related macular degeneration (ARMD) patients and therefore could be an attractive
therapeutic target. Notably, ERK1/2 pathway inhibitors are used in cancer therapy,
with severe and noncharacterized ocular side effects. To decipher the role of ERK1/2
in RPE cells, we conditionally disrupted the Erk1 and Erk2 genes in mouse RPE. The
loss of ERK1/2 activity resulted in a signiﬁcant decrease in the level of RPE65 expres-
sion, a decrease in ocular retinoid levels concomitant with low visual function, and a
rapid disorganization of RPE cells, ultimately leading to retinal degeneration. Our re-
sults identify the ERK1/2 pathway as a direct regulator of the visual cycle and a criti-
cal component of the viability of RPE and photoreceptor cells. Moreover, our results
caution about the need for a very ﬁne adjustment of kinase inhibition in cancer or
ARMD treatment in order to avoid ocular side effects.
KEYWORDS AP-1, ERK1/2, photoreceptors, RPE65, retinal degeneration, retinoid,
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Age-related macular degeneration (ARMD) is the most common cause of blindnessin individuals over 50 years of age. This pathology is characterized by the presence
of soft and/or hard drusen (extracellular debris and deposits), hyper- and hypopigmen-
tation of retinal pigment epithelium (RPE) cells, RPE and photoreceptor (PR) apoptosis,
as well as choroidal neovascularization (CNV) (1). Two subgroups of ARMD can be
distinguished: the dry form (geographic atrophy [GA]) and the wet form (exudative).
The dry form is characterized by the formation of drusen between RPE cells and Bruch’s
membrane (2). This accumulation is toxic for RPE cells, altering some of their important
functions. The wet form is linked to CNV affecting the subretinal macular region, which
eventually results in a loss of central vision.
An accumulation of intracellular lipofuscin occurs in both forms of ARMD. One of the
major components of lipofuscin is the retinoid derivative N-retinyl-N-retinylidene eth-
anolamine (A2E). A2E has a broad light absorption spectrum, with a peak in the blue
range (430 nm). Therefore, it is a potent photoinducible generator of reactive oxygen
species (ROS), which can damage proteins, lipids, and DNA of RPE cells (3–5). Even if
new imaging techniques did not reveal any correlation between the distribution of A2E
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and lipofuscin ﬂuorescence in the human RPE (6), it remains unclear whether metab-
olites or modiﬁed forms of A2E could be deleterious for the retina and RPE, especially
because A2E accumulation is linked to an increase of lipofuscin levels with age (7).
Moreover, the accumulation of A2E in phagolysosomes can lead to the inhibition of the
turnover of endogenous proteins in cultured RPE cells by abolishing the pH gradient
required for the normal function of these organelles (8). This damage leads to apoptosis
and impaired RPE cell functions. In addition, previous work from our laboratory showed
that A2E induces a strong decrease in extracellular signal-regulated kinase 1/2 (ERK1/2)
activity in polarized ARPE19 and isolated mouse RPE cells, and the inhibition of ERK1/2
leads to a signiﬁcant decrease in the level of retinal pigment epithelium-speciﬁc protein
of 65 kDa (RPE65) (9).
Mitogen-activated protein kinases (MAPKs) are evolutionarily conserved protein
kinases that transduce signals to regulate gene expression during cell proliferation,
survival, and differentiation (10–12). There are two different groups of MAPKs: the
conventional (ERK1/2/5, p38 kinases, and Jun N-terminal kinase 1/2/3 [JNK1/2/3]) and
the atypical (ERK3/4, ERK7, and Nemo-like kinase [NLK]) MAPKs (13). Due to their
important roles in cellular homeostasis, the abnormal regulation of conventional MAPK
pathways has been linked to a wide range of diseases (12, 14–17). The ERK1/2 pathway
in particular is commonly deregulated in human cancer, which has led to the devel-
opment and clinical evaluation of several small-molecule inhibitors targeting compo-
nents of this pathway (18, 19). Notably, the clinical beneﬁt of these molecules is limited
by mechanism-based side effects of blurred vision and altered light perception (20, 21).
Growing evidence indicates an important role of ERK1/2 signaling in retinal function.
Retina maturation is associated with the activation of ERK1/2, which was proposed to
play a survival role during development (22). We recently showed that ERK1/2 activity
is upregulated in RPE65 knockout (RPE65-KO) mice (23) and is decreased when ARPE19
cells are exposed to UV stress (24). Regeneration of chicken embryo retinas was found
to be associated with the ﬁbroblast growth factor (FGF)/FGF receptor (FGFR)/MEK/ERK-
dependent upregulation of the paired homeobox transcription factor PAX6 in the RPE
(25). Interestingly, a recent clinical study by the Dridi et al. revealed increased ERK1/2
activity in the RPE of patients suffering from GA as well as in a mouse model of RPE
degeneration induced by DICER1 depletion (26). These ﬁndings suggest a key role for
ERK1/2 in ARMD and support the concept of ERK1/2 inhibition as a possible treatment
for this disease (26). However, the ERK1/2 signaling pathway is complex, with multiple
roles in differentiation, proliferation, and cell death pathways, depending on the
cellular context. This complexity has been described in many studies (27, 28) and is a
central question in order to understand the role of these kinases before considering
whether to modulate their activity for therapeutic purposes.
Inhibitors of the ERK1/2 pathway used in cancer therapy may provoke ocular
secondary effects (21), yet this treatment has been proposed for ARMD (26). In fact, little
is known about the real impact of blocking these kinases in the mouse retina. Therefore,
in order to obtain valuable insights about ERK1/2 inhibition and to understand the role
of ERK1/2 signaling in the maintenance and survival of RPE cells, we established a
mouse line with an RPE-speciﬁc knockout of the Erk1 and Erk2 genes (RPE double
knockout [RPE-DKO]). Fundus analyses of mice with an RPE-speciﬁc loss of ERK1/2
showed macular depigmentation. Electroretinogram (ERG) analyses combined with
retinoid measurements revealed dysfunctional vision as well as a signiﬁcant decrease in
the ocular retinoid content. Optical coherence tomography (OCT) analyses conﬁrmed
the disorganization of the retinal structure, and immunohistochemical analyses dem-
onstrated RPE morphology alterations and the consequent loss of PRs. At the onset of
retinal degeneration, the loss of ERK1/2 led to a speciﬁc decrease in the level of RPE65
with the mislocalization of lecithin retinol acyltransferase (LRAT). The diminution of
RPE65 expression depended on the presence of an AP-1 site in the promoter region, as
C-FOS and FRA-1 (Fos-related antigen 1) protein expression levels are decreased and
binding to this AP-1 site is reduced in RPE-DKO mice.
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RESULTS
RPE-speciﬁc loss of ERK1/2 causes vision impairment due to a deﬁcit of reti-
noids. In order to establish a mouse line with an RPE-speciﬁc knockout of the Erk1 and
Erk2 genes, we used Erk1/ mice with a conditional allele of Erk2 (Erk1/; Erk2f/f) (29)
crossed with transgenic mice carrying the human vitelliform macular dystrophy 2
(VMD2) promoter-directed reverse tetracycline-dependent transactivator (rtTA) and
tetracycline-responsive element (TRE)-directed Cre (VMD2-rtTA/TRE-Cre) (30), called
RPE-Cre mice, to obtain VMD2-rtTA/TRE-Cre; Erk1/; Erk2f/f mice. Doxycycline treatment
of these mice leads to the disruption of Erk2 speciﬁcally in RPE cells. The VMD2-rtTA/
TRE-Cre; Erk1/; Erk2Δ/Δ (RPE-DKO) line was then compared to the Erk1/; Erk2f/f line
as control (CTL) mice.
We ﬁrst analyzed the visual function and retinal structure of RPE-DKO mice in
comparison to CTL mice. The doxycycline (Dox)-induced expression of Cre in RPE cells
was veriﬁed by crossing RPE-Cre animals with tdTomato mice (31) to generate RPE-
Cre-tdTomato mice. Two intraperitoneal (i.p.) injections of 10 g Dox, 1 week apart, at
2 months of age triggered the consistent expression of Cre speciﬁcally in RPE cells (Fig.
1A). This protocol was followed to induce Cre protein expression in 2-month-old
RPE-DKO mice, while 2-month-old CTL mice were injected with phosphate-buffered
saline (PBS). The genotypes of all mice were conﬁrmed by PCR ampliﬁcation of Cre, Erk1
KO, and Erk2 ﬂoxed alleles (Fig. 1B and C); the deletion of Erk2 in the RPE was conﬁrmed
FIG 1 Generation and characterization of CTL and RPE-DKO mice. (A) tdTomato ﬂuorescence of cryostat sections of ﬁxed
whole-mount eyes from Cre/tdTomato mice injected with either PBS or doxycycline (Dox). (B) Constructs used to generate
Erk1-KO and Erk2 conditional mice (Erk1/ Erk2f/f) and primers used to genotype the mice. Wt, wild type. (C) Representative
genotyping of Erk1/; Erk2/f mice (lane 1); Erk1/; Erk2f/f mice, called CTL mice (lane 2); and VMD2-rtTA/TRE-Cre; Erk1/;
Erk2Δ/Δ mice, called RPE-DKO mice, when injected with Dox (lane 3). (D) The speciﬁc loss of Erk2 in the RPE is conﬁrmed by
the delta fragment present in genomic DNA isolated from RPE cells from Erk1/; Erk2/f mice (lane 1), Erk1/; Erk2f/f mice,
called CTL mice (lane 2); and VMD2-rtTA/TRE-Cre; Erk1/; Erk2Δ/Δ mice, called RPE-DKO mice, when injected with Dox (lane
3). (E) Cryostat sections of ﬁxed whole-mount eyes from CTL and RPE-DKO mice at 1 month, immunostained as indicated. (F)
Western blot analysis of ERK1/2 expression in RPE protein lysates from CTL and RPE-DKO mice at 1 month. The ARPE19 protein
lysate is used as a positive control for ERK1 expression.
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by an analysis of RPE genomic DNA, as evidenced by the presence of the delta (Δ) band
(Fig. 1D). Immunostaining showed a decreased ERK2 level in the RPE of RPE-DKO mice
at 1 month in comparison to the level in control mice (Fig. 1E). In addition, Western blot
analysis of RPE protein lysates clearly showed the absence of ERK1 in both RPE-DKO and
CTL mice and a decreased ERK2 level only in RPE-DKO mice (Fig. 1F). Fundus analysis
showed an apparent depigmentation of RPE-DKO eyes (Fig. 2A). OCT analyses per-
formed on RPE-DKO mice at 4 months revealed the degeneration of the retina with a
signiﬁcant reduction of all retinal and choroidal layers (Fig. 2B). In accordance with this
result, ERG analyses revealed a signiﬁcant impairment of vision in RPE-DKO mice at 2
months, as revealed by the lower amplitude of the b wave in both the scotopic and
photopic stimulations (Fig. 2C). Scotopic patterns (50 mcd s/m2) demonstrated the
absence or severe reduction of a and b waves in RPE-DKO mice in comparison to CTL
mice, while photopic patterns (10 mcd s/m2) showed an absence of stimulation in
RPE-DKO mice (Fig. 2C, right). This clearly indicates impairments in both the cone and
rod photoreceptor responses to light stimuli in RPE-DKO animals.
The severe vision damage and retinal degeneration observed in RPE-DKO mice led
us to measure the relative amounts of visual cycle intermediates. Mice that had been
dark adapted for 12 h were enucleated under dim light. The retina was separated from
the choroid and subjected to high-performance liquid chromatography (HPLC) analyses
as previously described (32). The loss of ERK1/2 in the RPE led to a signiﬁcant decrease
in the level of ocular retinoids. Levels of retinyl esters in the choroid (dissected to
include RPE cells) were signiﬁcantly reduced. In the retinas of dark-adapted eyes,
decreases of more than half of the amounts of 11-cis-retinal and all-trans-retinal were
observed (Fig. 2D). We further intended to measure how light inﬂuences the ocular
retinoid composition of these mice. Thus, we exposed the mice to bright light, where
the turnover of the visual cycle is enhanced. As expected, we observed increases in the
amounts of all-trans-retinol and retinyl ester(s) after light treatment. Notably, the levels
of both retinoids were signiﬁcantly lower in RPE-DKO mice than in controls, indicating
an impairment of the visual cycle in both dark-adapted and light-exposed mice (Fig.
2D). We also noted, by immunostaining analysis, a decrease in the expression level of
the stimulated by retinoic acid 6 (STRA6) protein, the membrane receptor for retinol
binding protein found in the RPE in RPE-DKO mice at 1 month (data not shown). This
decrease suggests that a reduction of retinoid uptake from the circulation could
contribute to the diminished ocular retinoid levels in RPE-DKO mice.
RPE-speciﬁc loss of ERK1/2 causes signiﬁcant thinning of the ONL/INL. Visual
impairment along with retinal dysfunction led us to examine the photoreceptor
structure in RPE-DKO mice. Staining of various cone and rod markers was performed to
analyze the integrity of the distinct retinal layers. Retinal degeneration was observed
only in RPE-DKO mice. As controls, we used ERK1/; Erk2f/f mice treated with PBS
(CTL), ERK1/; Erk2f/f mice treated with Dox, and VMD2-rtTA/TRE-Cre; ERK1/; Erk2f/f
mice treated with PBS; none of these mice showed retinal degeneration (data not
shown). No toxic effect of Dox was observed in CTL (data not shown) or in Cre-
tdTomato (Fig. 1A) mice. RPE-DKO mice exhibited reductions in the levels of cone
markers as well as in the outer nuclear layer (ONL) and the inner nuclear layer (INL)
thicknesses. Levels of cone arrestin and GNAT2 showed marked decreases in RPE-DKO
mice at 2 months, and this effect was more pronounced at 4 months (Fig. 3A). The
important loss of cone markers occurred before the disappearance of the respective rod
markers, as shown by immunostaining of GNAT2 (Fig. 3A and B). The levels of the rod
markers rhodopsin and GNAT1 were slightly decreased in RPE-DKO mice, principally in
the ONL. In addition, the outer segment (OS) length was already smaller in RPE-DKO
mice at 2 months (Fig. 3A). Retinal degeneration could explain the absence of a marked
reduction of the GNAT1 protein expression level shown by Western blot analysis,
because both GNAT1 and tubulin levels were decreased, so the ratio was not changed.
Measurement of the thicknesses of the ONL and INL conﬁrmed clear decreases in both
cases, underlining the devastating effect of the loss of ERK1/2 on RPE cells (Fig. 3C). In
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FIG 2 Loss of ERK1/2 in the RPE leads to vision impairment. (A) Representative fundus images of CTL and RPE-DKO mice at 2 or 4 months. (B)
Representative OCT images of CTL and RPE-DKO mice at 4 months. (C) Graphs of the scotopic (n  10) and photopic (n  4) ERG responses (b
wave) of CTL and RPE-DKO mice at 2 months. (*, P  0.05; **, P  0.001). The right panel shows the scotopic (50 mcd s/m2) and photopic (10
mcd s/m2) ERG responses of CTL and RPE-DKO mice. (D) Chromatographs and quantiﬁcation of retinoids (retinol [ROL] and retinal [RAL]) measured
in the retina and in the RPE-choroid from mice at 1 month, which were dark adapted for 16 h, or measured in whole eyes (containing the retina,
RPE, and choroid) from mice (same conditions) exposed to 1,000 mA of light for 2 h.
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fact, ONL and INL thicknesses were reduced by 50% after only 2 months of ERK1/2 loss
and by up to 70% after 4 months (Fig. 3C). We found staining of both GNAT1 and
CONE-ARRESTIN in the RPE of RPE-DKO mice at 1 month, while no staining was
observed in the RPE of CTL mice, as expected (Fig. 3D); this information supports the
hypothesis of a defect in the phagocytosis process in these mice. Interestingly, ONL and
INL degenerations correlated with the level of cell death, as demonstrated by terminal
deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assays
performed on RPE-DKO and CTL mice (Fig. 3E). The decreases of the ONL and OS
thicknesses as well as the structural disorganization of the entire retina were conﬁrmed
by electron microscopy (EM) imaging, revealing the disruption of the inner segment (IS)
and OS of photoreceptor cells (Fig. 4A). This disruption and loss of the OS in particular
were quantiﬁed by measuring the ONL, OS, and IS lengths (Fig. 4B). A follow-up study
of the mice for 1 year showed the disappearance of the ONL and a drastic thinning of
the INL, with no staining for cones or rods. The only persistent staining was for glial
ﬁbrillary acidic protein (GFAP) in the ganglion cell layer (GCL) and glycine in the inner
plexiform layer (IPL) (Fig. 4C).
RPE-speciﬁc loss of ERK1/2 causes speciﬁc reductions in levels of cone markers.
Additional biochemical analyses were carried out in order to verify the loss of cone
photoreceptors. Western blot analysis of retinas from CTL and RPE-DKO mice showed
that the level of GNAT2, a speciﬁc cone marker, was signiﬁcantly reduced at 2 months
and was reduced by more than 60% at 4 months (Fig. 5A). However, at 4 months, we
observed a marked decrease in both ONL and INL thicknesses, which could not be due
only to cone photoreceptor loss. Indeed, at 2 months, the level of GNAT1 was already
slightly affected, while at 4 months, the difference was visible even if not signiﬁcant. At
4 months, the decreases in the levels of photoreceptor proteins were mirrored by
reductions in their mRNA levels. Quantitative PCR (qPCR) showed that the levels of
FIG 3 Loss of ERK1/2 in the RPE leads to photoreceptor degeneration. (A) Cryostat sections of ﬁxed whole-mount eyes from
CTL and RPE-DKO mice at 2 or 4 months, immunostained against different rod and cone markers, as indicated. (B)
Flat-mount retinal preparation from CTL and RPE-DKO mice at 4 months, immunostained as indicated. (C) Outer nuclear
layer (ONL) and inner nuclear layer (INL) lengths measured manually by using ImageJ. Data represent means  standard
errors of the means of results from four independent experiments. *, P  0.05. (D) GNAT1 and cone arrestin stainings from
CTL and RPE-DKO mice at 1 month. The presence of both photoreceptor markers was observed in the RPE of RPE-DKO mice
(white arrows). (E) TUNEL staining of cryostat sections of ﬁxed whole-mount eyes from CTL and RPE-DKO mice at 2 months.
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speciﬁc cone markers, including Gnat2, ConeArrestin, mOpsin, and sOpsin, were signif-
icantly decreased at 2 months and were decreased further by 60 to 80% at 4 months
(Fig. 5B). In agreement with data fromWestern blot studies, the levels of the speciﬁc rod
markers Gnat1 and Rho showed no difference at 2 months but declined at 4 months,
although the reduction was not statistically signiﬁcant. Retinal degeneration could
explain the absence of a signiﬁcant reduction in the level of GNAT1 protein expression
shown by Western blotting, because both GNAT1 and TUBULIN levels were decreased,
so the ratio was not changed.
Loss of ERK1/2 in the RPE causes RPE ultrastructural damage. The loss of vision
as well as the pronounced retinal degeneration in these mice prompted us to examine
the state of the RPE ultrastructure in RPE-DKO mice at 1 month by EM imaging. An
overview of the RPE-retina cell layers showed massive shrinkage of the RPE cell layer,
a disruption of Bruch’s membrane (BM), and PR degeneration (Fig. 6A). In order to
characterize the damage to the RPE-retinal layer in more detail, different layers were
observed separately and quantiﬁed. The BM ultrastructure was clearly disrupted, and
the thickness of the membrane was signiﬁcantly reduced (Fig. 6B). The RPE cell layer
exhibited massive shrinkage, as evidenced by the signiﬁcant reduction of its length (Fig.
6C). The ultrastructural damage to the RPE cell layer was accompanied by the accu-
mulation of mitochondria at the basolateral layer membrane, as demonstrated by the
signiﬁcant increase of the organelle area when normalized to the area of the cytosol
(Fig. 6C). The RPE cell layer of RPE-DKO mice contained structures enriched in mem-
branes that resembled phagolysosomes of the OS of the PR (Fig. 6D). This indicates that
phagocytosis of OS, one of the major functions of RPE cells, is impaired in RPE-DKO
mice. Conﬁrmation was obtained by the presence of GNAT1 and CONE-ARRESTIN in the
RPE of RPE-DKO mice at 1 month (Fig. 3D). Ultrastructural analysis demonstrated that
the RPE-speciﬁc loss of ERK1/2 caused massive alterations to the ultrastructures of not
FIG 4 Decreases of outer nuclear layer (ONL), outer segment (OS), and inner segment (IS) lengths from
the start of degeneration to complete absence in RPE-DKO mice at 1 year. (A) Electron microscopy
images of retina-RPE layers from CTL and RPE-DKO mice at 2 or 4 months. The bottom panel is a
magniﬁcation of the OS layer of photoreceptors (PR). (B) Measurement of ONL, OS, and IS from electron
microscopy images. Data represent means standard errors of the means of results from 3 experiments.
**, P  0.008. (C) Cryostat sections of ﬁxed whole-mount eyes from CTL and RPE-DKO mice at 1 year,
immunostained as indicated.
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only the RPE cell layer but also the BM and the retinal cell layer. The ultrastructural RPE
damage in RPE-DKO mice was conﬁrmed by ﬂat-mount RPE-choroid analysis. Phalloidin
staining revealed a disorganized RPE structure along with an increased RPE cell size,
including multinucleated cells (Fig. 6E). A total loss of RPE cells was observed in parts
of the retinas of RPE-DKO mice at 2 months (Fig. 6F).
FIG 5 Loss of ERK1/2 in the RPE causes speciﬁc reductions in the levels of cone markers. (A) Representative images
and quantiﬁcation graphs of retinal protein lysates from CTL and RPE-DKO mice at 1, 2, or 4 months. Data represent
means  standard errors of the means of results from 5 independent experiments (*, P  0.02; **, P  0.001). (B)
Quantiﬁcation graphs for qPCR performed on retinal extracts from CTL and RPE-DKO mice at 1, 2, or 4 months. RL8
was used as an internal control to normalize RNA expression. Results are expressed as a percentage of the value
for CTL mice and as means  standard errors of the means of results from 4 independent experiments (*, P  0.05;
**, P  0.003).
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ERK1/2 directly regulates RPE65 levels. We previously showed that the inhibition
of the ERK1/2 pathway in ARPE19 cells as well as in isolated mouse RPE cells leads to
a reduction of Rpe65 mRNA expression (9). This decrease was conﬁrmed by RPE65
immunostaining in RPE-DKO mice at 1 month and at 2 weeks, respectively (Fig. 7A and
B). In addition, we observed a mislocalization of LRAT, the enzyme upstream of RPE65
FIG 6 Loss of ERK1/2 in the RPE leads to massive ultrastructural changes in RPE-DKO mice at 1 month. (A) Representative electron
microscopy images showing different retinal and RPE cell layers (B, Bruch’s membrane; RPE, retinal pigment epithelium; OS, outer
segment; IS, inner segment; ONL, outer nuclear layer). (B) Representative electron microscopy image of Bruch’s membrane (Mbre) and the
underlying RPE cells and measurement of the length of Bruch’s membrane (*, P  0.0001). (C) Representative electron microscopy images
of the RPE cell layer and the underlying OS of the PR, measurement of the RPE length, and quantiﬁcation of the area of mitochondria (stars,
mitochondria) (*, P  0.015). (D) Electron microscopy images showing the accumulation of membrane-enriched phagolysosomes in the
RPE of RPE-DKO mice in comparison to CTL mice (white arrows). (E and F) RPE ﬂat mounts from CTL and RPE-DKO mice at 2 months,
immunostained against phalloidin and counterstained with DAPI.
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FIG 7 ERK1/2 directly regulates RPE65 expression. (A) Cryostat section of ﬁxed whole-mount eyes from CTL and RPE-DKO mice at 1 month,
immunostained as indicated. (B) Cryostat section of ﬁxed whole-mount eyes from CTL and RPE-DKOmice at 2 weeks, immunostained as indicated.
(C) qPCR analysis of mRNAs for the genes indicated, extracted from the RPE-choroids of CTL and RPE-DKO mice at 1 month. RL8 was used as an
internal control to normalize RNA expression. Results are expressed as a percentage of the value for CTL mice and as means  standard errors
of the means of results from 3 retinas. *, P 0.03. (D) Representative immunoblot and quantiﬁcation of RPE protein lysates from CTL and RPE-DKO
mice at 1 month, immunoblotted as indicated. **, P 0.0002 (n 5). (E) Luciferase assay for both RPE65 and LRAT promoters. HEK293 cells were
transfected and treated as indicated. Luciferase ﬂuorescence was normalized to -Gal ﬂuorescence. Data represent means  standard errors of
the means of results from 4 independent experiments. *, P  0.05 versus pGL2-Basic-RPE65; #, P  0.05 versus pGL2-Basic. (F) EMSA of the AP-1
complex in nuclei from ARPE19 cells treated or not with U0126. AP-1 DNA binding analysis of nuclear extracts of ARPE19 cells treated with either
U0126 or PD0325901. Data represent means  standard errors of the means of results from 3 independent experiments, expressed as a
percentage of the value for the control. *, P  0.02; **, P  0.002. (G) AP-1 DNA binding analysis of whole-cell extracts from mice at 1 month.
Data represent means  standard errors of the means of results from 3 independent experiments, expressed as a percentage of the control. *,
P  0.015; **, P  0.002 (n  6). Also shown is a representative immunoblot of RPE protein lysates from CTL and RPE-DKO mice at 1 month,
showing the expression of C-FOS and FRA-1; tubulin was used as a control.
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in the visual cycle, to the apical side of RPE cells in RPE-DKO mice, instead of the
basolateral side as observed in CTL mice (Fig. 7A and B). qPCR analysis conﬁrmed the
results of immunostaining and revealed that RPE65 but not LRAT expression was
signiﬁcantly decreased in RPE cells of RPE-DKO mice at 1 month (Fig. 7C). The RPE65
protein expression level, normalized to the TUBULIN expression level, was signiﬁcantly
reduced in RPE-DKO mice at 1 month (Fig. 7D). Notably, the promoter of RPE65 has
been shown to contain an AP-1 site, which is under the transcriptional control of the
AP-1 family of proteins (33). We thus carried out an in vitro luciferase reporter assay
using RPE65 (33) or LRAT (34) promoter constructs. Luciferase activity was detected
with both promoters transfected into the HEK293 cell line (Fig. 7E). Treatment with the
MEK1/2 inhibitor U0126 caused a signiﬁcant decrease of the activity of the RPE65
promoter, while no change in activity was observed when the luciferase reporter was
driven by the LRAT promoter. The addition of U0126 did not signiﬁcantly affect
luciferase activity when the AP-1 site in the RPE65 promoter reporter construct was
deleted, indicating that it is mandatory for regulation by ERK1/2. Next, we set out to
identify the downstream effectors of ERK1/2 that regulate this AP-1 site. Nuclear
proteins of ARPE19 cells showed strong binding to the AP-1 sequence, which was
reduced in the presence of a competitor AP-1 oligonucleotide as well as by treatment
with U0126 (Fig. 7F). In order to identify which factors regulated by ERK1/2 are part of
the AP-1 complex, nuclear extracts from ARPE19 cells were subjected to an AP-1
binding enzyme-linked immunosorbent assay (ELISA) that included individual AP-1
family transcription factors. The inhibition of the ERK1/2 pathway in ARPE19 cells, using
either U0126 or PD0325901, led to decreased C-FOS and FRA-1 protein binding to the
AP-1 sequence (Fig. 7F), whereas the inhibitors had no effect on c-JUN, JUN-B, and
JUN-D binding (data not shown). In order to investigate whether this effect is main-
tained in RPE-DKO mice, whole-cell protein lysates from isolated RPE cells were
subjected to an AP-1 DNA binding assay. Indeed, the binding of C-FOS and FRA-1 to
AP-1 was signiﬁcantly reduced (Fig. 7G), and C-FOS and FRA-1 protein expression levels
were decreased in the RPE of RPE-DKO mice at 1 month (Fig. 7G). Taken together, data
from analyses of cell cultures and the mouse model argue in favor of a direct regulation
of RPE65 gene expression by the ERK1/2 pathway via the binding of C-FOS and FRA-1
complexes to the AP-1 site in the upstream promoter region.
DISCUSSION
In order to evaluate the potential use of ERK1/2 pathway inhibitors in ARMD
treatment and to better understand the ocular side effects observed in cancer patients
treated with such inhibitors, we disrupted ERK1/2 expression speciﬁcally in RPE cells of
mice. We observed two major consequences. The ﬁrst consequence is the downregu-
lation of RPE65, the mislocalization of LRAT, and the depletion of the retinoid content.
This already occurs 1 month after ERK1/2 depletion, when retinal degeneration is just
beginning to be detected, as shown by chromatin compaction in ONL cells as well as
the shortening of the photoreceptor OS. The second consequence includes changes in
the morphology of the RPE and in the RPE cell death process, which appears later, 2
months after Cre induction, when most of the hallmarks of retinal degeneration are
visible in the eyes of RPE-DKO mice.
RPE65 is an enzyme involved in vitamin A metabolism in RPE cells (35). This key
protein of the visual cycle catalyzes the transformation of all-trans-retinyl to 11-cis-
retinol. Mutations in RPE65 are associated with several retinal disorders, including
retinitis pigmentosa (RP), Leber congenital amaurosis (LCA) (36), and early-onset retinal
dystrophy (RD) in children (37). Much effort has been devoted to deciphering the roles
of various genetic mutations that are linked to these diseases (38). However, little is
known about how the activity of RPE65 is regulated at the RPE cell level. Several studies
analyzed the promoter region of the RPE65 gene (33, 39), but little is known about the
factors involved in its transcriptional regulation. Retinoic acid has been suggested to
participate in the downregulation of RPE65 (40) and of fatty acid transporter protein 4
(FATP4) and elongation of very-long-chain fatty acid protein 1 (ELOVL1) (41). Recently,
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Masuda and colleagues provided evidence for an involvement of sex-determining
region Y box-containing gene 9 (SOX9) in the regulation of the transcription of visual
cycle genes, including RPE65, retinaldehyde binding protein 1 (RBP-1) and retinal
G-protein-coupled receptor (RGR). They showed that SOX9 acts synergistically with
orthodenticle homeobox 2 (OTX2) to activate RPE65 gene expression (42). Here we
identify another critical upstream regulatory factor for RPE65. We demonstrate that the
disruption of ERK1/2 speciﬁcally in RPE cells leads to a marked decrease of RPE65
expression that occurs through an AP-1 site present in the promoter region of the
RPE65 gene. The inhibitory effect of U0126 on reporter gene expression was completely
abrogated when the AP-1 site was removed, even if we cannot exclude that other
regulatory elements close to the AP-1 sequence were also deleted from the construct;
this could explain the low promoter activity observed in the absence of the AP-1
sequence. The key roles of C-FOS and FRA-1 were conﬁrmed by Western blot analysis
and by an AP-1 DNA binding assay. Interestingly, ERK1/2 and SOX9 signaling pathways
were recently shown to interact in urothelial carcinoma (43) and zebraﬁsh sex deter-
mination (44). Moreover, the activation of ERK1/2 is associated with the activation of
the Wnt/-catenin pathway (45, 46), which plays a key role in the expression of the
RPE-speciﬁc transcription factors microphthalmia-associated transcription factor (MITF)
and OTX2 (47). In conjunction with protein paired box 6 (PAX6), MITF and OTX2 are key
factors in RPE development (48).
ERG analysis combined with the measurement of ocular retinoid levels revealed the
impaired vision of RPE-DKO mice. The signiﬁcant decrease in the level of retinoids and
histological evidence of retinal degeneration explain the absence of an ERG response
in these mice. The RPE plays critical roles in providing nutrients to the adjacent retina
and in the recycling of the visual chromophore. Upon absorption of light, 11-cis-retinal
isomerizes to all-trans-retinal in the outer segments of the photoreceptors, and the RPE
is necessary for the subsequent regeneration of the chromophore throughout the
visual cycle (49). The loss of ERK1/2 leads to a decrease in the level of RPE65, and
therefore, one would expect retinyl ester(s) to accumulate in RPE cells, as reported
previously for RPE65 mutant mice (50). However, for RPE-DKO mice, we observed a
signiﬁcant decrease in the level of retinyl ester(s) in both dark- and light-exposed eyes.
Therefore, in addition to RPE65 downregulation, which could explain the decrease in
the level of 11-cis-retinal, other pathological alterations in the RPE must account for the
decreased levels of ocular retinoids. We found a mislocalization of LRAT, which is
expressed mostly at the apical region of RPE cells in RPE-DKO mice, in comparison to
its normal basolateral localization (51). This mislocalization could affect LRAT activity
and explain the decreased levels of all-trans-retinyl esters. Moreover, we also measured
a lower expression level of STRA6, an RPE membrane receptor for the retinol binding
protein responsible for retinyl ester transport. Because STRA6 and LRAT work together
to retrieve retinoids from the blood circulation (52), such diminution may explain the
reduction of the retinoid content observed in RPE-DKO mice. These results phenocopy
some of the phenotypes observed for Stra6/ mice, including low retinoid content,
the lack of an ERG response, decreases of BM and RPE lengths, and altered morphology
of RPE cells (53).
The alteration of the RPE morphology in RPE-DKO mice was already visible at 1
month. Whole mounts of RPE from CTL mice show mono- and binucleated hexagonal
RPE cells with an apex shared by three cells, while RPE-DKO mice exhibit an unusual RPE
morphology, with a total disappearance of the RPE in some parts of the retina 2 months
after ERK1/2 depletion, whereas other parts display large cells with an irregular shape
and multinucleation (Fig. 6). RPE multinucleation, which has been reported for humans
(54), could result from a cytokinesis defect. The involvement of cytokinesis defects as
well as RPE dysfunctions and RPE cell death in aging eyes was recently described (55).
As the ERK1/2 MAPK pathway plays a key role in cell proliferation, we can envisage that
these kinases might be involved in the process. The sustained activation of ERK1/2 is
necessary for the progression from G1 phase to S phase and is associated with the
upregulation of proliferation-associated genes and the downregulation of antiprolif-
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erative genes (56). Moreover, ERK1/2 signaling is necessary to allow the entry of RPE
cells into cell cycling and RPE cell proliferation (57). In addition to its role in cell cycle
control, ERK1/2 is also implicated in centrosome orientation (58), which is crucial for
cytokinesis. Thus, we postulate that a disruption of ERK1/2 in the RPE induces defects
in cell cycle progression, leading ﬁrst to the multinucleation of the RPE and then to RPE
cell death. Whereas central RPE cells are senescent, peripheral cells proliferate, and
ERK1/2 could be important for their maintenance (59, 60). Retinal regeneration in the
chicken embryo was shown to be dependent on the FGF/FGFR/MEK/ERK-dependent
upregulation of PAX6 (25). The activation of the ERK1/2 pathway was also responsible
for the 15-deoxy-Δ12,14-prostaglandin J2 (dPGJ2)-dependent protection of RPE cells
from oxidative injury (61). These data point not only to a protective role of the ERK1/2
pathway in RPE cells but also to its participation in the maintenance and proliferation
of these cells, at least in the peripheral region. Our data indicate that the ablation of
ERK1/2 in 2-month-old adult RPE cells almost completely abrogated vision by initiating
early cone-speciﬁc degeneration, followed by rod impairment. Surprisingly, we ob-
served a decrease of GNAT1 immunostaining in Cre-DKO mice at 2 and 4 months, which
was not observed by either qPCR or Western blot analysis. At the same time, we clearly
detected a decrease in the ONL length, and thus, even if the total GNAT1 retinal content
decreases, the tubulin abundance decreases in parallel so that the GNAT1/tubulin ratio
is not modiﬁed. One outstanding question is why cones are more affected than rods in
this model. The dependence of cone PR survival on RPE65 was reported previously (62);
therefore, the direct regulation of RPE65 by ERK1/2 could account, at least in part, for
the severe cone dystrophy found in RPE-DKO mice. Moreover, inadequate 11-cis-retinal
production has been shown to be associated with cone degeneration, although the
mechanisms are currently not well understood (63–65). Measurement of retinoid levels
speciﬁcally in the retina of RPE-DKO mice revealed a signiﬁcant decrease in the level of
11-cis-retinal, which could contribute to rapid cone degeneration. This ﬁnding suggests
that the cone-speciﬁc effect seen at 2 months could be directly attributed to the role
of ERK1/2 in regulating RPE65 activity and 11-cis-retinal production that are critical for
cone PR survival.
Previously reported observations demonstrated that PR degeneration in Rpe65/
mice caused a massive activation of ERK1/2 in the GCL of the retina (23), probably in
order to protect the retina against stress induced by the absence of RPE65. However,
we recently showed that in polarized ARPE19 cells and isolated mouse RPE, A2E
treatment decreases phospho-ERK1/2 signiﬁcantly, along with a reduction of the RPE65
level. In addition, the inhibition of the ERK1/2 pathway by U0126 also induces a
signiﬁcant decrease in the level of RPE65 expression (9). The role of ERK1/2 in RPE cells
has not been the subject of detailed investigation. Our study showing that the loss of
ERK1/2 leads to RPE cell death, retinal atrophy, and degeneration strongly supports a
signiﬁcant role for ERK1/2 in the maintenance and survival of RPE cells. Defects of RPE
cells and RPE cell death will lead to PR degeneration. Consistently, these features were
observed in a mouse model of genetic RPE ablation using mice that expressed
inducible diphtheria toxin A (DTA) speciﬁcally in the RPE. In this RPECreER/DTA model,
functional analysis showed very low scotopic and photopic ERG responses as well as PR
degeneration (66). Accordingly, interactions of PRs with the RPE are essential for PR
survival (67).
The very rapid INL degeneration observed in RPE-DKO mice is more difﬁcult to
explain. Even if Cre expression is observed speciﬁcally in RPE cells, as shown for
Cre-tdTomato mice (Fig. 1) and as previously described (30), we also noted the ectopic
expression of Cre in IPL vessels (but not in choroidal vessels) in certain mice. Therefore,
we cannot totally exclude that ERK1/2 was also depleted in some IPL vessels, which may
impact INL degeneration. We also hypothesize that the absence of key factors normally
secreted by the RPE may inﬂuence INL degeneration. Further analyses are required in
order to decipher the mechanisms leading to INL degeneration in ERK1/2-depleted
mice.
Several MEK1/2 inhibitors have been clinically evaluated for cancer therapy, but
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some of these early-phase trials were stopped prematurely because of toxicity issues,
including various ocular adverse effects (21, 68–70). Treatments last approximately 3
weeks and are repeated every month (71, 72). Such long-term treatment with multiple
doses of highly potent MEK inhibitors lead to a marked and sustained inhibition of
ERK1/2 activity, phenocopying in part the impact of the double knockout. We observed
a signiﬁcant decrease of the RPE65 expression level already at 2 weeks (Fig. 7B), while
mRNA and protein levels of this RPE marker were decreased by about 50% at 1 month
(Fig. 7C and D). Our study provides evidence for a key role of ERK1/2 signaling in the
eye and, more speciﬁcally, in RPE cells. The ablation of ERK1/2 signaling reduces RPE65
expression levels, leads to decreased retinoid levels, affects the RPE and the retinal
structure, and induces retinal degeneration. Therefore, the use of ERK1/2 pathway
inhibitors in ARMD treatment, as recently suggested (26), has to be reevaluated, taking
into consideration the ﬁndings reported here. Fine-tuning of ERK1/2 inhibition will be
necessary in order to block only the negative effects of high kinase activity and restore
low ERK1/2 activity without impacting the role of this kinase in RPE cells.
MATERIALS AND METHODS
Animals. Studies involving mice adhered to the Association for Research in Vision and Ophthalmol-
ogy (ARVO) statement for the use of animals in ophthalmic and vision research (https://www.arvo
.org/content-detail/level2-about2/policies2/statement-for-the-use-of-animals-in-ophthalmic-and-visual
-research/) and were approved (permit number VD3023) by the Veterinary Service of the State of Vaud
(Switzerland). Animals were maintained in a 12-h-light/12-h-dark cycle and had unlimited access to food
and water. The generation of Erk1//Erk2ﬂ/ﬂ mice was reported previously (29). The RPE-speciﬁc loss of
ERK1/2 (VMD2-rtTA/TRE-Cre; Erk1/; Erk2Δ/Δ [RPE-DKO]) was created by crossbreeding an Erk1//Erk2f/f
mouse with a mouse expressing the Cre recombinase driven by the human VMD2 (RPE-Cre) promoter
and inducible by doxycycline (30) to ﬁrst obtain VMD2-rtTA/TRE-Cre; Erk1/; Erk2f/f mice. Two months
after birth, VMD2-rtTA/TRE-Cre; Erk1/; Erk2f/f mice were then injected twice, 1 week apart, with 10 g
of Dox in 500 l PBS in order to induce the Cre recombinase; we call these mice RPE-DKO mice. As a
control, Erk1//Erk2f/f mice were injected in a similar way with PBS; we call these mice CTL mice. Every
time period mentioned in the experiments refers to the amount of time after Dox injection (e.g., an
RPE-DKO mouse at 2 months is a 4-month-old mouse treated after 2 months and analyzed 2 months
later, after Cre induction and ERK1/2 depletion). Cre-tdTomato mice were created by crossbreeding
VMD2-rtTA/TRE-Cre mice with tdTomato mice (31) to set up the Dox injection protocol and visualize Cre
expression. Genotyping of mice was carried out by using PCR analysis with genomic DNA isolated from
ear punches (Direct PCR [Ear]; Viagen). All the mice were veriﬁed to have the mutant Rd1-negative
genotype. The mice were processed for fundus, OCT, and ERG analyses or sacriﬁced for other functional
assays 2 weeks, 1 month, 2 month, 4 months, or 1 year after the second injection.
Cell culture. HEK293T cells were cultured in high-glucose Dulbecco’s modiﬁed Eagle’s medium
(DMEM) containing 25 mM HEPES. The cells were passaged every 2 to 3 days. A total of 600,000 cells were
seeded into a P60 plate and transfected after 24 h by using a calcium-phosphate transfection kit (GE
Healthcare) with the indicated plasmids, according to the manufacturer’s instructions. When indicated,
cells were treated with 10 nM U0126 (Cell Signaling Technology) or 2 M PD0325901 (Cell Signaling
Technology) for 24 h and lysed with lysis buffer (20 mMmorpholinepropanesulfonic acid [MOPS] [pH 7.0],
2 mM EGTA, 5 mM EDTA, 30 mM sodium ﬂuoride, 60 mM -glycerophosphate [pH 7.2], 20 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1% Triton X-100) before analysis.
Noninvasive experiments. Mice were anesthetized by i.p. injection of 10 mg of xylazine/kg of body
weight plus 80 mg/kg ketamine. Mydriatic agents (0.5% tropicamide for 2 min and 10% phenylephrine
hydrochloride for 1 min) were applied on the eye for pupil dilation and to block eyebrow movement. The
fundi of age-matched CTL and RPE-DKO mice were photographed. OCT was carried out on age-matched
CTL and RPE-DKO mice by using an OCT system (Micron III; Phoenix Research Laboratories), according to
the manufacturer’s recommendations, at 4 months and 1 year.
For scotopic ERGs, age-matched CTL and RPE-DKO mice were dark adapted overnight before
anesthesia and the application of the mydriatic agents as described above. For photopic ERGs, mice were
exposed to bright light of 3 cd for 10 min. Full-ﬁeld ERGs were recorded by using the HMsERG system
(Ocuscience).
Immunohistochemistry. Enucleated eyes were ﬁxed in 4% paraformaldehyde (PFA)–PBS for 45 min,
followed by cryoprotection in 30% sucrose–PBS. Ten-micrometer embedded frozen sections were further
processed for immunohistochemistry. Brieﬂy, frozen retina sections were blocked in PBS with 3% normal
goat serum (Sigma-Aldrich) and 0.2% Triton X-100 (Sigma-Aldrich) for 1 h at room temperature (RT) and
incubated with primary antibodies in blocking buffer overnight at 4°C. The following primary antibodies
were used: cone arrestin (Merck Millipore), rhodopsin (Rho 1D4, a kind gift of Robert J. Moldy), mOpsin
(Chemicon), STRA6 (Abcam), GNAT1 (Santa Cruz Biotechnology), GNAT2 (Santa Cruz Biotechnology),
RPE65 (Pin5, a kind gift of Andreas Wenzel), LRAT (Santa Cruz Biotechnology), GFAP (Chemicon), and
glycine (ImmunoSolution) antibodies. Sections were incubated again in blocking buffer for 30 min at RT
before incubation with the secondary antibodies for 1 h at RT. Secondary or ﬂuorescence-labeled
antibodies were a goat anti-mouse antibody–Alexa Fluor 488 conjugate, a goat anti-mouse antibody–
Pyakurel et al. Molecular and Cellular Biology
December 2017 Volume 37 Issue 24 e00295-17 mcb.asm.org 14
Alexa Fluor 594 conjugate, a goat anti-rabbit antibody–Alexa Fluor 488 conjugate, a goat anti-rabbit
antibody–Alexa Fluor 594 conjugate, and Oregon Green 488-phalloidin (Thermo Fisher Scientiﬁc).
Incubation with the secondary antibody alone was used as a negative control. Tissue sections were
counterstained with 4=,6-diamidino-2-phenylindole (DAPI) to identify retinal cell layers.
For ﬂat-mount choroid-RPE structures, dissected choroid-RPE sections were mounted onto a
coverslip, ﬁxed in 4% PFA–PBS for 45 min, and processed for immunolabeling with Oregon Green
488 as described above. A TUNEL assay (Roche Life Science) was carried out as described previously
(23).
Tissue isolation, mRNA extraction, and protein preparation. Enucleated eyes from CTL and
RPE-DKO mice were dissected under a microscope to exclude extraocular tissues. The cornea, lens, iris,
and vitreous body were removed, and the retina was extracted. Either the retina, the RPE, or the
RPE-choroid was processed for protein/mRNA isolation.
For mRNA extraction, either the retina or the RPE-choroid was resuspended in TRIzol reagent
(ThermoFisher) and stored at 80°C until further handling. RPE mRNA was extracted by using a
previously described protocol (73), while retinas and RPE-choroids were extracted by using the following
protocol. Brieﬂy, 0.1 volumes of sodium acetate, 1 volume of phenol, and 0.2 volumes of chloroform were
added to the tube and mixed, and phase separation was allowed for 15 min on ice. One volume of
isopropanol and 2 l of glycogen (5 g/l) were added to the upper aqueous phase and left to
precipitate at 20°C overnight. Following centrifugation at 10,000  g for 10 min at 4°C, the precipitate
was washed with 75% ethanol (EtOH) and allowed to dry at RT before being resuspended in diethyl
pyrocarbonate (DEPC)-treated double-distilled water (ddH2O). Quantitative PCR was carried out as
described previously (23), using 100 nM primers. The sets of primers used for genotyping (Fig. 1B) and
reverse transcription-PCR (RT-PCR) can be found in Table 1.
Protein isolation from retinas was performed by two successive homogenizations of the retina with
syringes (23 gauge and 26 gauge) on ice, followed by 3 freeze-thaw cycles. RPE cell lysates were prepared
as previously described (74). Brieﬂy, the incised RPE-choroid was incubated in radioimmunoprecipitation
assay (RIPA) buffer (50 mM Tris [pH 8.0], 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS)
for 10 min with shaking. The choroid was transferred to a different tube, leaving the shredded RPE cells
on the tube wall.
For Western blot analysis, extracted retinas were resuspended in lysis buffer (20 mM MOPS [pH 7.0],
2 mM EGTA, 5 mM EDTA, 30 mM sodium ﬂuoride, 60 mM -glycerophosphate [pH 7.2], 20 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1% Triton X-100, and 1 M dithiothreitol [DTT] plus
protease inhibitors), while the RPE were resuspended in RIPA buffer (50 mM Tris [pH 8.0], 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS). All samples were conserved at 80°C until further
processing. Extracted cell lysates were separated by SDS-PAGE and transferred onto nitrocellulose
membranes (Millipore). The membranes were probed by using the indicated primary antibodies and
TABLE 1 Primers used for genotyping and qPCR
Purpose Gene Primer Sequence
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isotype-matched secondary antibodies conjugated to ﬂuorescent dye (Licor Biosciences) and detected by
using the Odyssey imaging system (Licor). The following primary antibodies were utilized: GNAT1 (Santa
Cruz Biotechnology), GNAT2 (Santa Cruz Biotechnology), ERK1/2 (Cell Signaling Technology), -tubulin
(Sigma-Aldrich), and RPE65 (Pin5) antibodies. The following secondary bodies were applied: IRDye 680RD
(Licor Biosciences) and IRDye 800CW (Licor Biosciences).
Luciferase and AP-1 binding assays. Luciferase activity in cell lysates was measured by using a
coenzyme A-coupled assay system with luciferin and ATP (Promega). Ten micrograms of cell lysates
was mixed with 20 l of luciferase assay reagent in 4 triplicates. Luminescence was read by using
kinetic software on a 384-well-plate spectrophotometer (PerkinElmer). Beta-galactosidase (-Gal)
activity was measured by using a luminescent substrate endpoint assay. Twenty micrograms of
lysates was mixed with 50 l 2 -Gal buffer (120 mM Na2HPO4, 80 mM NaH2PO4, 2 mM MgCl2, and
100 mM -mercaptoethanol [-ME]) and 50 l 2 ONPG (2-nitrophenyl--D-galactopyranoside). The
absorbance at 412 nm was read.
An AP-1 binding assay (TransAM AP-1 kit; Active Motif) was carried out, as described previously (24),
on nuclear extracts from ARPE19 cells. Brieﬂy, cells were resuspended in 1 ml cold buffer A (10 mM HEPES
[pH 7.9], 10 mM KCl, 1 mM DTT, and protease inhibitors) and placed on ice for 15 min. Next, 12.5 l of
10% NP-40 was added, and the supernatant was discarded after centrifugation. Nuclei were lysed in
buffer B (20 mM HEPES [pH 7.9], 400 mM NaCl, 1 mM DTT, and protease inhibitors) and quantiﬁed for
protein content. Eight micrograms of the nuclear protein extract or 15 g of whole-cell protein extracts
was used for the AP-1 binding assay according to the manufacturer’s instructions.
AP-1 EMSA. An AP-1 electrophoretic mobility shift assay (EMSA) was carried out on nuclear extracts
from HEK293 cells that were either left untreated or treated with U0126 according to the provider’s
protocol (Odyssey Infrared EMSA kit; Licor Biosciences). In brief, the nuclear extract was incubated with
a solution containing 25 mM DTT–2.5% Tween 20, 1 g/l poly(dI·dC), 1% NP-40, 100 mM MgCl2, and
the IRDye 700 AP-1 consensus oligonucleotide (5=-CGCTTGATGACTCAGCCGGAA-3=) in either the pres-
ence or the absence of the AP-1 (in italics) competitor oligonucleotide. Binding was performed for 20
min, after which the sample was loaded onto a 5% native acrylamide gel in the presence of a loading
dye. Fluorescence was detected on a Licor Odyssey scanner.
Retinoid measurement. Age-matched CTL and RPE-DKO mice were either dark adapted over-
night or exposed to bright light of 1,000 mAH for 2 h. For dark conditions, the retina was separated
from the RPE-choroid layer. For bright-light conditions, the whole eye was processed for measure-
ment. Ocular tissues were transferred to a 2-ml reaction vial, and 200 l of 2 M hydroxylamine (pH
6.8) and 200 l of methanol were added. All steps were conducted under red safety light (	600 nm)
to avoid retinoid isomerization. Tissues were mechanically ground by using a Bio-Gen PRO200
homogenizer (Fisher Scientiﬁc). The homogenized extracts were allowed to stand for 10 min for
oxime formation. Next, 400 l of acetone and 500 l of hexane were added. The samples were
vortexed, and the aqueous and organic phases were separated by centrifugation at 5,000  g
(Minispin Plus; Eppendorf). The organic phase was removed, and extraction was repeated with 500
l of hexane. Collected organic phases were pooled, dried with a SpeedVac (Eppendorf) at 30°C, and
redissolved in HPLC mobile-phase solvent. HPLC analysis was carried out with an Agilent 1260
Inﬁnity Quaternary HPLC system (Santa Clara) equipped with a pump (catalog number G1312C) with
an integrated degasser (catalog number G1322A), a thermostated column compartment (catalog
number G1316A), an autosampler (catalog number G1329B), a diode array detector (catalog number
G1315D), and online analysis software (Chemstation). The analyses were carried out at 25°C by using
a normal-phase Zorbax Sil (5-m, 4.6- by 150-mm) column (Agilent Technologies) protected with a
guard column with the same stationary phase. For retinoid separation, the column was developed
with 90% hexane and 10% ethyl acetate at an isocratic ﬂow rate of 1.4 ml · min1. For molar
quantiﬁcation of retinoids, the HPLC system was scaled with authentic retinoid standards.
Electron microscopy. Enucleated whole mouse eyes were ﬁxed in a 2.5% glutaraldehyde solution
(Electron Microscopy Sciences) in phosphate buffer (PB) (0.1 M, pH 7.4) (Sigma-Aldrich) for 90 min
at RT. Ocular tissues were then postﬁxed with a fresh mixture of 1% osmium tetroxide (Electron
Microscopy Sciences) with 1.5% potassium ferrocyanide (Sigma-Aldrich) in PB during 1 h 30 min at
RT. The samples were then washed three times in distilled water and dehydrated in graded
concentrations of an acetone solution (Sigma-Aldrich) (30% for 20 min, 70% for 20 min, 100% for 1
h, and 100% for 2 h). This was followed by inﬁltration in graded concentrations of Epon (Sigma-
Aldrich) (Epon-acetone for 2 h at a 1:3 dilution, 2 h at a 3:1 dilution, and 4 h and 12 h at a 1:1 dilution)
and, ﬁnally, polymerization for 48 h at 60°C in an oven. Ultrathin sections of 50 nm were cut
transversally on a Leica Ultracut microtome (Leica Microsystems) and picked up on a 2- by 1-mm
nickel slot grid (Electron Microscopy Sciences) coated with polystyrene ﬁlm (Sigma-Aldrich). Sections
were poststained with 4% uranyl acetate (Sigma-Aldrich) in H2O during 10 min, rinsed several times
with H2O followed by 0.4% Reynolds’ lead citrate (75) in H2O (Sigma-Aldrich) during 10 min, and
rinsed several times with H2O.
Micrographs were taken with a Philips (now FEI Company) CM100 transmission electron microscope
at an acceleration voltage of 80 kV with a TVIPS TemCam-F416 digital camera (TVIPS GmbH).
Molecular biology. pGL2-Basic-RPE65(450/39) was a kind gift from Debra Thompson (University
of Michigan). pGL3-Basic-LRAT(268/257) was a kind gift from Catharine Ross (University of Pennsyl-
vania). pGL2-Basic-RPE65(450/39) (33) was digested with BglII and StuI and religated in order to
remove the AP-1 site (190 bp segment from the start codon).
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